AI Article Synopsis
- The study investigates the effectiveness of using α-particle radioimmunotherapy targeting stem cells in treating acute myelogenous leukemia (AML) through experiments on tumor-bearing mice.
- The pharmacokinetics of the At-labeled anti-CXCR4 monoclonal antibody showed a biological half-life of 15 hours, with peak tumor uptake at 6 hours yielding a high tumor-to-muscle ratio.
- Radiation dosimetry results indicate specific absorbed doses in various organs, suggesting that this targeted therapy is promising and warrants further investigation.
Article Abstract
To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody (At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of At-CXCR4 mAb in blood was 15.0 h. The highest tumor uptake of 5.05%ID/g with the highest tumor-to-muscle ratio of 8.51 ± 6.14 was obtained at 6 h. Radiation dosimetry estimated with a human phantom showed absorbed doses of 0.512 mGy/MBq in the bone marrow, 0.287 mGy/MBq in the kidney, and <1 mGy/MBq in other major organs except bone. Sphere model analysis revealed 22.8 mGy/MBq in a tumor of 10 g; in this case, the tumor-to-bone marrow and tumor-to-kidney ratios were 44.5 and 79.4, respectively. The stem-cell-targeted α-particle therapy using At-CXCR4 mAb for AML appears possible and requires further therapeutic studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176675 | PMC |
| http://dx.doi.org/10.1038/s41598-020-63557-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!